Clearmind Medicine Inc. CMND

Annual Quarterly

No annual revenue total was found in Clearmind Medicine Inc.'s SEC filings.

Clearmind Medicine Inc. (CMND) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Oct 31, 2025 it held $3.9 million in cash and investments and $18,800 in total debt.

Revenue
—
Net income
$-3.86M
+26.6% vs prior year
Operating cash flow
$-4.73M
+2.6% vs prior year
Free cash flow
—
EPS
$-30.35
+55.2% vs prior year
Dividend per share
None
Shares outstanding
158,076
-96.3% vs prior year
Net cash
$3.90M
FY 2025
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CMND (Nasdaq)
Fiscal year ends
October 31
Incorporated in
Canada (Federal Level)
Headquarters
Vancouver, British Columbia, Canada (Federal Level)
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1892500

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Oct 31, 2025
FY 2024
Oct 31, 2024
FY 2023
Oct 31, 2023
Net income
-$3.9M
-$5.3M
-$8.6M
Diluted EPS
-$30.35
-$67.80
-$1,703.04
Operating cash flow
-$4.7M
-$4.9M
-$6.3M
Total assets
$6.1M
$7.3M
$6.0M
Total liabilities
$4.9M
$4.1M
$5.0M
Stockholders' equity
$1.2M
$3.1M
$983,472
Cash and investments
$3.9M
$6.6M
$5.4M
Total debt
$18,800
$53,142
—

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) Oct 27, 2026 Oct 27, 2026
6-K Current report (foreign issuer) Oct 16, 2026 Oct 16, 2026
6-K Current report (foreign issuer) Oct 13, 2026 Oct 13, 2026
6-K Current report (foreign issuer) Oct 8, 2026 Oct 8, 2026
6-K Current report (foreign issuer) Oct 7, 2026 Oct 7, 2026
6-K Current report (foreign issuer) Sep 30, 2026 Sep 30, 2026

All 372 Clearmind Medicine Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.